Xenetic Biosciences, Inc. Announces Research and Development Collaboration with Scripps Research to Advance XCART(TM) Platform May 19, 2020
Xenetic Biosciences, Inc. Reports First Quarter 2020 Financial Results and Provides Corporate Update May 14, 2020
Xenetic Biosciences' Webcast Replay from Noble Capital Markets' 16th Annual Investor Conference Presentation Now Available Feb 27, 2020
Xenetic Biosciences, Inc. Appoints Accomplished Biopharmaceutical Executive, Greg MacMichael, Ph.D. to Scientific Advisory Board Feb 26, 2020
Xenetic Biosciences, Inc. Strengthens Expertise to Advance XCART Development Program with Appointment of Cell Therapy Expert, Maksim Mamonkin, Ph.D. to Scientific Advisory Board Feb 13, 2020
Xenetic Biosciences, Inc. to Present at Noble Capital Markets' 16th Annual Investor Conference Feb 11, 2020
Xenetic Biosciences, Inc. Announces Publication of Data from Partner's Phase 1/2 Study Evaluating Program Leveraging Polyxen(R) Platform Technology Jan 14, 2020
Xenetic Biosciences, Inc. Reports Third Quarter 2019 Financial Results and Provides Corporate Update Nov 15, 2019
